Associated tags: Singular, RNA, Genomics, PX, Medicine, Protein, NGS, OMIC, SAN, G4, Proteomics, Science, Spatial analysis
Locations: SAN DIEGO, CA, US, GOLDMAN, FLORIDA
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida.
Key Points:
- SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, Florida.
- Singular Genomics’ management is scheduled to participate in a fireside chat Wednesday, June 12, 2024, at 7:40 a.m. Pacific Time / 10:40 a.m. Eastern Time.
- Investors and other interested parties are invited to listen to a live and recorded webcast of the presentation at investor.singulargenomics.com in the Presentations & Events section.
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024.
Key Points:
- SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the first quarter ended March 31, 2024.
- Shipped six G4 systems in the first quarter of 2024, increasing the total number of commercial systems shipped to 30 as of the end of the first quarter of 2024.
- Gross profit was negative $0.4 million in the first quarter of 2024, compared to $0.1 million in the first quarter of 2023.
- Operating expenses for the first quarter of 2024 totaled $26.4 million, compared to $25.4 million for the first quarter of 2023.
Singular,
Growth,
SAN,
Tissue,
NGS,
RNA,
Proteomics,
Workflow,
Investment,
Genomics,
OMIC,
Network throughput,
H&E,
Video game “We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.
Key Points:
- “We ended 2023 on a strong note, shipping our largest number of quarterly instruments to-date,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.
- Shipped eight G4 systems in the fourth quarter of 2023, increasing the total number of commercial systems shipped to 24 as of the end of the fourth quarter of 2023.
- Operating expenses for the fourth quarter of 2023 totaled $24.8 million, compared to $22.5 million for the fourth quarter of 2022.
- Operating expenses included non-cash stock-based compensation of $2.7 million for the fourth quarter of 2023 and $3.1 million for the fourth quarter of 2022.
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024.
Key Points:
- SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024.
- The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Investors interested in listening to the conference call may do so by dialing 1-877-545-0523 for domestic callers or 1-973-528-0016 for international callers and using conference ID 476908 approximately five minutes prior to the start time.
- A live and archived webcast of the event will be available at investor.singulargenomics.com , in the Presentations & Events section.
Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.
Key Points:
- Singular unveiled the G4X™ Spatial Sequencer as a high-throughput in situ spatial sequencing platform capable of simultaneous direct RNA sequencing, targeted transcriptomics, proteomics and fluorescent H&E from formalin-fixed, paraffin-embedded (FFPE) tissues.
- As an upgrade to the G4® Sequencing Platform, the G4X is expected to position Singular to be the only company worldwide to offer capabilities for tissue-based in situ spatial multiomics and NGS on the same instrument.
- The G4X Spatial Sequencer is on display at the conference, alongside performance data from technology access collaborations with top academic centers.
- Singular also announced updates to the G4, the industry-leading benchtop sequencing system for speed, flexibility, and power.
Genomics,
Tumor microenvironment,
SAN,
Protein,
Workflow,
Cell,
RNA,
Gene editing,
Research,
PX,
Bone marrow,
Haematopoietic system,
OMIC,
AML,
Harvard Medical School,
Proteomics,
Associate professor,
NGS,
Tissue,
Acute leukemia,
Network throughput,
Medical imaging The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.
Key Points:
- The G4X is designed to offer high-throughput in situ direct sequencing of RNA (Direct-Seq™), targeted transcriptomics, and proteomics profiling from formalin-fixed, paraffin-embedded (FFPE) tissues.
- The G4X Spatial Sequencer is designed to offer novel capabilities, stackable data streams, and unprecedented throughput for spatial profiling of tissue.
- Its novel capabilities will include Direct-Seq, which is the sequencing of RNA molecules in situ and has the potential to open new areas of scientific discovery.
- Singular also plans to provide G4X Spatial Sequencing Technology Access Services starting in the second quarter of 2024.
SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
Key Points:
- SAN DIEGO, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced instrument shipments and preliminary unaudited revenue for the fourth quarter of 2023.
- The Company shipped eight G4 instruments in the fourth quarter of 2023.
- Preliminary unaudited revenue for the fourth quarter of 2023 is expected to be approximately $1.0 million, representing growth of approximately 31% compared to $765 thousand during the fourth quarter of 2022.
- Singular Genomics plans to release its full fourth quarter and 2023 financial results in March 2024.
Retrieved on:
Tuesday, November 14, 2023
SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023.
Key Points:
- SAN DIEGO, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2023.
- Shipped five G4 systems in the third quarter of 2023, increasing the total number of commercial systems shipped to 16 as of the end of the third quarter of 2023.
- Operating expenses for the third quarter of 2023 totaled $24.5 million, compared to $24.7 million for the third quarter of 2022.
- Operating expenses included non-cash stock-based compensation of $2.8 million for the third quarter of 2023 and $3.4 million for the third quarter of 2022.
Retrieved on:
Thursday, November 2, 2023
Singular,
Laboratory,
Microfluidics,
RNA,
SBS,
Cell,
NGS,
Partnership,
Fluency,
Chemistry,
Fine chemical WATERTOWN, Mass., Nov. 2, 2023 /PRNewswire/ -- Fluent BioSciences, a cutting-edge life science company transforming single cell analysis through simple, cost-effective, and highly scalable single-cell RNA sequencing solutions, is excited to announce a partnership with Singular Genomics, a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians.
Key Points:
- WATERTOWN, Mass., Nov. 2, 2023 /PRNewswire/ -- Fluent BioSciences, a cutting-edge life science company transforming single cell analysis through simple, cost-effective, and highly scalable single-cell RNA sequencing solutions, is excited to announce a partnership with Singular Genomics, a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians.
- Together, they unveil the compatibility of PIPseq™ Single Cell RNA Kits with sequencing on the Singular Genomics G4® Sequencing Platform.
- Complimenting PIPseq's innovation, the Singular Genomics G4 Sequencing Platform sets a new standard in benchtop sequencing.
- The integration of PIPseq sample preparation with the G4 Platform equips both seasoned and novice researchers with the essential tools for efficient, cost-effective, and scalable single cell analysis within any laboratory setting.
Retrieved on:
Tuesday, October 24, 2023
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023.
Key Points:
- SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023.
- The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 616134 approximately five minutes prior to the start time.
- A live and archived webcast of the event will be available at investor.singulargenomics.com , in the Presentations & Events section.
